14 results about "Tumor resistance" patented technology

This invention relates to the application of exosomes in reversing tumor resistance to immune checkpoint (PD-1) inhibitors. A novel application of exosomes in the preparation of pharmaceutical compositions reversing tumor resistance to immune checkpoint inhibitors is disclosed. Exosomes generated from tumor cells recombinantly expressing adenylate cyclase 7 (ADCY7) can significantly reverse tumor resistance to PD-1 inhibitors, and the exosomes exhibit a synergistic effect with the PD-1 inhibitors.

The invention relates to the field of biological medicines, in particular to application of an MAGEB16 regulator in preparation of products for treating autoimmune diseases or resisting tumors. The invention provides an application of an MAGEB16 regulator in preparation of a product for treating autoimmune diseases or resisting tumors. The invention also provides an antibody combined with the surface of a tumor cell or an antigen binding fragment thereof. The application finds that the MAGEB16 protein can be expressed on the surface of a tumor cell, so that the technical scheme of directly targeting the MAGEB16 on the surface of the tumor cell through an antibody or a nucleic acid molecule and a series of technical schemes of targeting the MAGEB16 on the surface of the tumor cell become feasible technical schemes, and a new technical scheme is provided for efficient tumor resistance.

The present disclosure is directed to the interplay between tumor associated macrophages (TAMs) and tumor cells in the TME. SLC13A3 is demonstrated as a transporter for itaconate in tumor cells and plays a previously unreported role in tumor resistance to ferroptosis and ICB. Compositions and methods for blocking the function of SLC13A3's tumor protecting function are described.

Disclosed are a lactylated NBS1 protein and uses thereof. A lactylation site in this application is lysine at position 388 of NBS1 protein. Lactylation at K388 site of the NBS1 protein activates the DNA repair pathway and has multiple functions, including promoting radiotherapy and chemotherapy resistance in tumor cells and enhancing homologous recombination in DNA repair. By targeted inhibition of the lactylated NBS1 protein, tumor resistance to radiotherapy or chemotherapy can be reversed, providing a potential target for reversing tumor resistance to radiotherapy or chemotherapy.

The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a combination of kaempferol-3-O-[2-O-(6-O-E-feruloyl)-β-D-glucopyranose]-β-D-pyranose and E-6-O-p-coumaroylpaederoside methyl ester in tumor resistance or the preparation of an anti-tumor drug. The research of the present invention has shown that both a kaempferol-3-O-[2-O-(6-O-E-feruloyl)-β-D-glucopyranose]-β-D-pyranose compound monomer and an E-6-O-p-coumaroylpaederoside methyl ester compound monomer have very strong anti-tumor activity. In the in-vivo anti-tumor activity research, the inhibition rates thereof can reach 48.97% and 45.96%, respectively; and when both are combined to inhibit tumor cells, the research reveals that the two monomers have an obvious effect of synergistically inhibiting tumors.

The invention relates to an anti-prothrombin / phosphatidylserine antibody, a pharmaceutical composition and an application of the anti-prothrombin / phosphatidylserine antibody. The anti-prothrombin / phosphatidylserine antibody provided by the invention is connected with a prothrombin / phosphatidylserine compound with high affinity, so that the antibody is combined with phosphatidylserine in a targeted manner to achieve the treatment of tumor resistance, infection resistance, thrombosis resistance, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease and Parkinson's disease.

The invention relates to a method for producing an anthraquinone compound by using actinomycetes Nocardiopsis aegyptia HDN19-252, and a preparation method of the anthraquinone compound. The invention also relates to an application of the compound in tumor resistance. The structural formula is shown in the specification. A fermentation product containing the compound can be obtained through fermentation culture of actinomycetes Nocardiopsis aegyptia HDN19-252, and then the compound is obtained through separation and purification by adopting normal-phase silica gel column chromatography, reversed-phase C-18 column chromatography, semi-preparative HPLC (High Performance Liquid Chromatography) and other methods. The invention aims to provide a novel compound which is novel in structure and has human metastatic pancreatic adenocarcinoma cell (AsPC-1) inhibitory activity from secondary metabolites derived from actinomycetes, and the compound can be used as a novel pancreatic cancer cell inhibitor for treating pancreatic cancer.

The invention discloses a nano acanthopanax preparation medicine and a preparation method thereof, and relates to the technical field of acanthopanax preparation, and the acanthopanax preparation medicine comprises water, a plant raw material composition, a nano carrier material, an antioxidant, a surface modifier, a preservative, a coloring agent and a vitamin composition. Meanwhile, the antioxidant added in the prescription and the pH environment optimized in the process protect active ingredients of the acanthopanax from oxidative degradation, and provide potential passive or active targeting ability for anti-tumor, anti-inflammatory and other applications of the acanthopanax; the natural conformation and activity of heat-sensitive active ingredients are reserved to the maximum extent through the mild preparation process, management, visualization and storage are carried out on preparation data of the acanthopanax senticosus preparation medicine and corresponding analysis results, management of the acanthopanax senticosus preparation medicine through internet cloud management and control is facilitated, and the intelligent level of management of the acanthopanax senticosus preparation medicine is improved.

The invention relates to a preparation method and application of injectable nano-motor hydrogel. The preparation method comprises a preparation method of nano-motors (NMs) and a preparation method of injectable hydrogel. The NMs move autonomously by taking oxygen as a power source, and the nano particles are formed by self-assembly of bowl-shaped polydopamine nano particles (PDA NBs), nano platinum (Pt NPs) and hexadecacarboxyl zinc phthalocyanine (ZnPc) through intermolecular interaction. Hydrogen peroxide (H2O2) is used as fuel, and Pt NPs catalyzes H2O2 to generate O2, so that the nano bowl is pushed to move. The gel material of the injectable hydrogel is chitosan, and the injectable hydrogel with good stability can be prepared by adjusting the proportion of different components. The injectable nano-motor hydrogel prepared by the invention has a wide application prospect in the fields of drug sustained release, tumor resistance and the like.

The invention relates to a novel organic arsine compound Z2-A-Z2 and an application of the novel organic arsine compound Z2-A-Z2 in tumor resistance. The organic arsine compound Z2-A-Z2 disclosed by the invention not only shows remarkable anti-DLBCL activity in an in-vitro experiment, but also can effectively induce tumor cell apoptosis; in an animal model, the compound also shows a good anti-tumor effect, has no obvious toxic or side effect and has an important clinical application value. As an epigenetic regulating agent, Z2-A-Z2 not only shows good anti-tumor activity to DLBCL, but also has the characteristics of low toxicity and high selectivity, and has clinical transformation potential. Besides, Z2-A-Z2 can also be applied to other malignant tumors (such as multiple myeloma and T cell lymphoma) depending on an epigenetic mechanism, or can be combined with existing targeted drugs and immunotherapy, so that the comprehensive curative effect of tumor treatment is improved.

The invention discloses an application of an ethyl piperazine chromene compound in tumor resistance, and belongs to the technical field of medical chemistry. The ethyl piperazine chromene compound is 3-(4-chlorphenyl)-8-[(4-ethyl piperazine-1-yl) methyl]-7-hydroxy-2H-chromene-2-ketone, and the structural formula of the ethyl piperazine chromene compound is shown in the description. Experiments prove that the compound has a relatively strong inhibition effect on various human tumor cells such as breast cancer HCC1806, osteosarcoma MG63, liver cancer LM3, colorectal cancer HCT-8 and the like. Wherein under the concentration of 5 [mu] M, the survival rate of the compound to HCC1806 cells is inhibited to 9.4%, a strong inhibition effect on the intractable breast cancer subtype is shown, and a comprehensive result shows that the ethyl piperazine chromene compound can provide a new candidate molecule for broad-spectrum antitumor drugs.

The invention discloses a novel TCR-CAR plasmid for expressing flagellin, a CAR-T cell, a preparation method of the novel TCR-CAR plasmid and the CAR-T cell, and application of the novel TCR-CAR plasmid and the CAR-T cell in tumor resistance, and belongs to the technical field of CAR-T cells. By means of the innovative structural design, after CAR recognizes a target antigen, expression and secretion of flagellin can be started along with activation of T cells, the flagellin is released to a tumor site, after an activation signal disappears, release of the flagellin gradually fades away, and after the target antigen is recognized again, a new round of secretion and release is started. The technical problems that in the prior art, release of flagellin polypeptide cannot be accurately controlled, engineering immune cells release randomly, and then the anti-tumor effect cannot be achieved due to the fact that the engineering immune cells cannot effectively enter the tumor in the application of treating solid tumors can be effectively solved.

The invention belongs to the technical field of microorganisms, and discloses clostridium RJ-1 for producing collagenase, a product containing the clostridium and application of the clostridium RJ-1 in tumors. The strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on June 27, 2024, and the preservation number is GDMCC 64809. The bacterial strain simultaneously expresses collagenase and generates iron-containing particles through mineralization in bacteria, the secreted collagenase degrades existing collagen grids and shows degradation characteristics related to collagen concentration, the released iron-containing particles generate ferrous ions in a lysosome acid environment after self-dissolution, and the iron-containing particles generate iron ions in the lysosome acid environment. Ferroptosis is subsequently induced by a Fenton reaction with cellular uptake. In a tumor mouse model with dense collagen, good tolerance can be achieved through single intravenous injection, huge tumors with the size of about 1000 mm < 3 > can be rapidly dissolved, and potential clinical application value is shown.

Relates to a polyethylene glycol micromolecule medicine and a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula I or pharmaceutically acceptable salts thereof, intermediate compounds as shown in a formula II and a formula V thereof, a method for preparing the compound, and an application of the compound in tumor resistance. Biological tests show that the compound has a remarkable inhibiting effect on tumors such as breast cancer, intestinal cancer, non-small cell lung cancer, melanoma, oral squamous cell carcinoma and osteosarcoma.